CardiologyNOW: A Pri-Med Virtual Conference | Pri-Med

Join your clinician colleagues and expert faculty for CardiologyNOW: A Pri-Med Virtual Conference on Friday, December 3. This free remote learning experience includes:

  • A carefully curated CME/CE curriculum, moderated by Peter Libby, MD
  • Interactive, live Q&A with distinguished faculty, including experts from top healthcare institutions across the country
  • The opportunity to earn up to 3.00 AMA PRA Category 1 Credits™ and 3.00 ABIM Medical Knowledge MOC Points, or 3.00 AANP contact hours of continuing education, including 1.67 hours of pharmacology
  • Access to on-demand CME/CE courses

Your free registration includes the full conference, but you're welcome to join the sessions that best fit your schedule. Agenda and details are subject to change.

To register for this virtual conference, you will be asked to sign in to your Pri-Med account. If you do not have an account, you can create your free account now, which takes less than two minutes.


  CME/CE Accredited Session

Non-CME/CE Session
Sponsored by Industry

Click For Session Details
Session Times Listed in ET

8–9am ET    CME/CE Accredited Session



With the COVID-19 pandemic moving through the country, it is important for clinicians to have the most up-to-date information. Join this session with Dr. Peter Libby to learn about the cardiovascular complications of COVID-19 and how you can help patients facing these issues.

Peter Libby, MD

Cardiovascular Specialist, Brigham and Women's Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, MA

9:10–10:10am ET    CME/CE Accredited Session



In recent years there has a been paradigm shift in how to individualize use of antihyperglycemic agents in people with type 2 diabetes, with cardiac history and risk factors significantly affecting the guideline-recommended agents. In addition metformin, SGLT2 inhibitors and GLP-1 receptor agonists have become an integral part of treatment of patients with diabetes and comorbid cardiac and renal disease. Join expert faculty in this data driven session as they review the and discuss strategies to improve use of these agents in management of type 2 diabetes.

Christopher Cannon, MD

Cardiovascular Division, Brigham and Women's Hospital, Professor of Medicine, Harvard Medical School, Boston, MA

Tina Kaur Thethi, MD, MPH

Associate Investigator and Endocrinologist, AdventHealth, Translational Research Institute, Orlando, FL

Supported by Novo Nordisk Inc.

10:20–11:05am ET    Non-CME Industry Theater



Sponsored by Janssen Pharmaceuticals, Inc.

11:15–12:15am ET    CME/CE Accredited Session



The development of cardio-oncology as a clinical field has been driven by improved therapeutics resulting in a dramatic increase in the number of cancer survivors (~17,000,000 in the United States alone), many of whom suffer cardiovascular complications related to their cancer treatments. Both "traditional" and "targeted" therapies can affect the cardiovascular system resulting in hypertension, heart failure, myocarditis, arrhythmias, vascular disease, and thrombosis. While recurrence of cancer is the eventual cause of death in many "cancer survivors," cardiovascular disease is responsible for substantial morbidity and mortality in this population. Thus, effective means of mitigating cardiovascular complications of cancer therapies would have substantial impact on health. Here we will review novel issues in cardio-oncology and will give a broad overview of this emerging field.

Javid Moslehi, MD

Associate Professor of Medicine, Director, Cardio-Oncology Program, Co-Director, Vanderbilt Program for Optimizing Immuno-oNcology Therapy (V-POINT), Vanderbilt School of Medicine, Nashville, TN

12:25–1:10pm ET    Non-CME Industry Theater



Sponsored by Industry Sponsor here